rss rss rss rss rss OncoVista Innovative Therapies   OTC BB: OVIT
Home | Contact Us | 210.677.6000
OVI-123


 

  • A Phase I/II clinical-stage drug
     
  • Active against TdT-positive leukemias
     
  • IP: Patent protection through 2014
     
  • Next generation analogs: 2023
     
  • Status: Phase I/II clinical trial on-going at two sites in the US
     
  • Orphan Drug Designation obtained
     
  • Relevant Biomarker: TdT
     
  • Estimated Market Potential: >$350M
     

Cordycepin (3’-deoxyadenosine), a nucleoside analog, is OncoVista’s first clinical-stage development compound.

The compound was obtained through a merger with Aengus Pharmaceuticals which was completed in January 2006.

Cordycepin is a Phase I/II clinical stage drug candidate for treatment of refractory Acute Lymphoblastic Leukemia (ALL) patients who express the enzyme terminal deoxynucleotidyl transferase (TdT).

A Phase I/II clinical trial is currently enrolling and treating patients at two sites in the US: Dana Farber Cancer Institute (Boston MA) and the Cancer Treatment and Research Center (San Antonio TX)

 

Investor Resources

img

Investor Information Brief
Adobe PDF Format, ~1.4MB
Opens in a New Browser Window

SEC Filings

Section 16 (Insider) Filings
Opens in a New Browser Window

Alex Weis - Steve Crowley interview

Opens in a new browser

Alex Weis - Jordan Kimmel interview

Opens in a new browser

contact

OncoVista is dedicated to providing safe, innovative and efficacious treatments for cancer.
Follow the links below or contact us to learn more about our industry-leading products, technologies and people.

Our Products.